• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Thursday, January 21, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Personalized medicine leads to better outcomes for patients with cancer

Bioengineer by Bioengineer
June 6, 2016
in Cancer
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In a meta-analysis of hundreds of clinical trials involving thousands of patients, researchers at University of California San Diego School of Medicine report that therapeutic approaches using precision medicine, which emphasizes the use of individual genetics to refine cancer treatment, showed improved response and longer periods of disease remission, even in phase I trials.

The findings are published in the June 6, 2016 issue of JAMA Oncology.

After reviewing 346 phase I clinical trials involving 13,203 patients, the authors found that in precision medicine treatment arms more than 30 percent of patients responded to treatment compared to 4.9 percent of patients enrolled in non-personalized arms. Patients treated with precision medicine also benefited from longer progression-free survival with a median of 5.7 months before their disease worsened compared to 2.95 months for the others.

tumblr_static_apxs292juk0s8o48s8gcgk8o4_640_v2

“Our analysis shows that in the era of precision medicine, phase I clinical trials using personalized therapy with a biomarker-based approach can do more than assessing the toxicity and side effects,” said Maria Schwaederlé, PharmD, lead author and UC San Diego Moores Cancer Center researcher at the Center for Personalized Cancer Therapy. “These early trials can result in improved outcomes for patients, even among people whose disease is resistant to standard treatments, by selecting patients who will respond best using a personalized approach from the start.”

The study involved 58 precision medicine treatment arms and 293 that did not. Personalized arms led to improved outcomes across tumor types. The use of a personalized approach was associated with higher response rate of 24.5 percent in patients with solid tumors compared to 4.5 percent in non-personalized strategies. Similarly, blood cancers had a 24.5 percent response rate compared to 13.5 percent. In both tumor types, using precision medicine gave patients a longer progression-free survival (4.1 versus 2.8 months in solid tumors and 13.6 versus 4 months in hematologic tumors).

In a sub-analysis of 234 arms testing targeted drugs, the authors found that using biomarkers to assign patients to treatments led to response rates of 31.1 percent compared to 5.1 percent for those that did not. This shows the importance of pairing targeted therapy with a biomarker.

Another sub-analysis of the precision medicine trials showed that while the use of both genomic and protein biomarkers improved outcomes, genomic biomarkers performed better. Targeting genomic alterations resulted in a 42 percent response rate compared to a 22.4 percent response if the biomarker was directed at a protein overexpression.

“What we observed is that phase I trials can serve both to inform us on the effectiveness of new therapies as well as identify patients likely to benefit most if a personalized approach is employed,” said Razelle Kurzrock, MD, director of the Center for Personalized Therapy and Clinical Trials Office at Moores Cancer Center and senior author of the paper. “Another important point is that targeted drugs in and of themselves are often quite useless if not combined with a patient’s individual tumor biomarkers to determine whether they are likely to benefit from a particular therapy.”

###

Additional study co-authors include: Melissa Zhao, UC San Diego; J. Jack Lee, University of Texas MD Anderson Cancer Center; Vladimir Lazar, Worldwide Innovative Network for Personalized Cancer Therapy; Brian Leyland-Jones, Avera Cancer Institute; Richard L. Schilsky, Worldwide Innovative Network for Personalized Cancer Therapy and American Society of Clinical Oncology; and John Mendelsohn, Worldwide Innovative Network for Personalized Cancer Therapy and University of Texas MD Anderson Cancer Center.

This research was funded, in part, by the Joan and Irwin Jacobs Fund.

Media Contact

Yadira Galindo
[email protected]
619-543-6163
@UCSanDiego

http://www.ucsd.edu

The post Personalized medicine leads to better outcomes for patients with cancer appeared first on Scienmag.

Share12Tweet7Share2ShareShareShare1

Related Posts

IMAGE

NUS scientists find new mechanism of cancer formation

January 19, 2021
IMAGE

Novel organoid models: Illuminating path to cervical cancers

January 19, 2021

A master cancer gene hijacks a ‘molecular crowbar’ to make breast cancer cells invasive

January 19, 2021

How to find mutated sperm? Just go FISH

January 19, 2021
Next Post
blank

Rice study details stress-diabetes link

blank

A new approach to chemical synthesis

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    The map of nuclear deformation takes the form of a mountain landscape

    54 shares
    Share 22 Tweet 14
  • People living with HIV face premature heart disease and barriers to care

    63 shares
    Share 25 Tweet 16
  • New drug form may help treat osteoporosis, calcium-related disorders

    40 shares
    Share 16 Tweet 10
  • New findings help explain how COVID-19 overpowers the immune system

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

GeneticsPublic HealthCell BiologyBiologyClimate ChangeMaterialsEcology/EnvironmentInfectious/Emerging DiseasesTechnology/Engineering/Computer SciencecancerChemistry/Physics/Materials SciencesMedicine/Health

Recent Posts

  • Late rainy season reliably predicts drought in regions prone to food insecurity
  • Internet and freedom of speech, when metaphors give too much power
  • Cancer can be precisely diagnosed using a urine test with artificial intelligence
  • Antibiotic resistance may spread even more easily than expected
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In